Ultratrace Iobenguane I131
Phase 2Small molecule
Ultratrace Iobenguane I131 is one of 99 small molecule programs targeting Paraganglioma. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
237 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Paraplatin
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Camptosar
PfizerPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Adriamycin
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Paraganglioma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ultratrace Iobenguane I131. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details